Get the Stockscreener App
11.38
3.74%
0.41
Abcellera Biologics Inc stock is traded at $11.38, with a volume of 12.31M.
It is up +3.74% in the last 24 hours and up +68.84% over the past month.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
See More
Previous Close:
$10.97
Open:
$10.84
24h Volume:
12.31M
Relative Volume:
1.52
Market Cap:
$3.49B
Revenue:
$79.21M
Net Income/Loss:
$-143.96M
P/E Ratio:
-23.73
EPS:
-0.4796
Net Cash Flow:
$-189.60M
1W Performance:
+64.21%
1M Performance:
+68.84%
6M Performance:
+267.10%
1Y Performance:
+152.89%
1-Day Range:
$10.47
$11.50
1-Week Range:
$8.40
$11.50
52-Week Range:
$2.745
$11.50
Abcellera Biologics Inc Stock (ABCL) Company Profile
Name
Abcellera Biologics Inc
Sector
Industry
Phone
(604) 559-9005
Address
150 W 4TH AVENUE, VANCOUVER
Compare ABCL vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABCL
Abcellera Biologics Inc
|
11.38 | 3.17B | 79.21M | -143.96M | -189.60M | -0.4796 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-07-25 | Resumed | Leerink Partners | Outperform |
| Aug-20-24 | Downgrade | The Benchmark Company | Buy → Hold |
| Feb-22-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Dec-05-23 | Initiated | KeyBanc Capital Markets | Overweight |
| Nov-06-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Oct-13-23 | Resumed | Piper Sandler | Overweight |
| Feb-28-23 | Initiated | Cowen | Outperform |
| Dec-15-22 | Initiated | Goldman | Buy |
| Nov-16-22 | Initiated | Truist | Buy |
| Dec-21-21 | Initiated | The Benchmark Company | Buy |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Jan-05-21 | Initiated | BMO Capital Markets | Outperform |
| Jan-05-21 | Initiated | Berenberg | Buy |
| Jan-05-21 | Initiated | Credit Suisse | Outperform |
| Jan-05-21 | Initiated | SVB Leerink | Outperform |
| Jan-05-21 | Initiated | Stifel | Buy |
View All
Abcellera Biologics Inc Stock (ABCL) Latest News
Can AbCellera Biologics (ABCL)’s Vertex Pharmaceuticals Incorporated (VRTX) Deal Turn its TCE Platform Into a Breakthrough? - Yahoo Finance
AbCellera Biologics Inc. • Robinhood Token (ABCL) Price, MarketCap, Charts and Fundamentals Info - BeInCrypto
AbCellera CFO Andrew Booth Acquires 37,200 Shares at $10.32 Each - Kalkine Media
AbCellera Biologics Director Michael R. Hayden Acquires 46,387 Shares at $10.37 Average Price - Kalkine Media
AbCellera Biologics | 4: Statement of changes in beneficial ownership of securities-Officer Booth Andrew - Moomoo
AbCellera (ABCL) Q2 2026 Earnings Call Transcript - AOL.com
AbCellera Biologics Stock 6-Day Winning Spree: Stock Climbs 85% - Trefis
6 Green Days In A Row: AbCellera Biologics Stock Is Up 85% - Trefis
AbCellera prices US $200M offering at US $9.75 a share - Private Capital Journal
AbCellera Biologics | 424B5: Prospectus - Moomoo
AbCellera Biologics | 4: Statement of changes in beneficial ownership of securities-Director Hayden Michael R - Moomoo
National CineMedia Posts Downbeat Q2 Results, Joins Borr Drilling, AbCellera Biologics And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session - Sahm
AbCellera Director Michael R. Hayden Donates 50,000 Shares to Charity via Genworks 2 Consulting - Kalkine Media
AbCellera Biologics Announces Oversubscribed $200 Million Offering - TipRanks
AbCellera Enters Underwriting Agreement for $187M Equity Offering With Jefferies, J.P. Morgan - TradingView
AbCellera Biologics Inc. • Robinhood Token (ABCL) Price Prediction for 2026 to 2031 - Bybit
AbCellera Biologics (NASDAQ:ABCL) Sees Large Volume IncreaseTime to Buy? - MarketBeat
AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile - AOL.com
Funding Roundup: Silence Therapeutics, AbCellera Announce IPO Pricing, Beyang, Remepy Close Series A Financing - Pharmaceutical Executive
Abcellera Biologics Inc Nasdaq ABCL Canada F-35 Fighter Jet Purchase (hA9yM7fsuE) - Mshale
ABCL Looks 82.6% Overvalued on GF Value™ - GuruFocus
AbCellera prices $200 million public offering at $9.75/share - Investing.com
AbCellera prices $200 million public offering at $9.75/share By Investing.com - Investing.com Nigeria
AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants - lincolnjournal.com
AbCellera Biologics stock analysis: momentum vs. fundamentals By Investing.com - Investing.com Canada
AbCellera Biologics stock analysis: momentum vs. fundamentals - Investing.com
What's Going on With AbCellera Biologics Stock On Wednesday? - Benzinga
AbCellera Biologics (NASDAQ:ABCL) Shares Gap DownHere's Why - MarketBeat
Revenue Downgrade: Here's What Analysts Forecast For AbCellera Biologics Inc. (NASDAQ:ABCL) - Moomoo
National CineMedia Posts Downbeat Q2 Results, Joins Borr Drilling, AbCellera Biologics And Other Big Stoc - benzinga.com
ABCL News | ABCELLERA BIOLOGICS INC (NASDAQ:ABCL) - ChartMill
AbCellera offers up USD 200m in stock to support NK3 menopause antibody - AllSci
AbCellera Biologics Inc. (NASDAQ:ABCL) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
ABCL StockAbCellera Biologics Inc Stock Breaking News Today | ABCL Stock Price Ifc (po852VQ6WV) - Mshale
AbCellera’s ABCL635 Meets Primary Endpoints in Phase 2 for Menopause Symptoms - The Clinical Trial Vanguard
AbCellera Biologics (ABCL) Stock Sees Fair Value Lift After Clinical Data And Jazz Deal - Yahoo Finance
AbCellera Biologics (ABCL) On ABCL635 Trial Results And A Richer Valuation Story - simplywall.st
Truist raises AbCellera stock price target on trial results By Investing.com - Investing.com South Africa
AbCellera launches $200-million equity offering on heels of strong menopause trial results - The Globe and Mail
AbCellera launches $200 million public offering of common shares By Investing.com - Investing.com UK
ABCL Looks 72.1% Overvalued on GF Value™ - GuruFocus
Why is Abcellera Biologics stock sliding today? - Investing.com
AbCellera Biologics (ABCL) Could Be 33% Overvalued Following ABCL635 Phase 2 Results - Yahoo Finance
AbCellera stock falls on $200M public offering launch By Investing.com - Investing.com India
AbCellera stock falls on $200M public offering launch - Investing.com
AbCellera: Excellent Phase 2 Data In Menopause But The Platform Narrative Is Fading - Seeking Alpha
AbCellera launches $200 million public offering of common shares - Investing.com
AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - Business Wire
ABCL Maintained by Truist Securities -- Price Target Raised to $30 - GuruFocus
AbCellera Shares Jump on Trial Results Amid Interest in Menopause Drugs - Moomoo
Truist Financial Issues Positive Forecast for AbCellera Biologics (NASDAQ:ABCL) Stock Price - MarketBeat
Abcellera Biologics Inc Stock (ABCL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):